Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

Lupus

Volumn 14, Issue 12, 2005, Pages 947-952

  Tse, K C ^a   Li, F K ^a   Tang, S ^a   Tang, C S O ^a   Lai, K N ^a   Chan, T M ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Angiotensin receptor blocker (ARB); Angiotensin converting enzyme inhibitor (ACEI); Lupus nephritis; Proteinuria

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DETERIORATION; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLOMERULOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOSARTAN; LUPUS NEPHRITIS; MALE; PROTEINURIA; RAMIPRIL; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 30644460076     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2249oa     Document Type: Article

References (31)

1. Austin HA III, Klippel JH, Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986; 314: 614-19.
2. Houssiau FA, Vasconcelos C, D'Cruz D el al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
3. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med 2000; 343: 1156-62.
4. Chan TM, Tse KC, Tang CSO, Mok MY, Li FK, for the Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16(4): 1076-84.
5. Donadio JV Jr. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 1992; 7(suppl 1): 97-104.
6. Sloan RP, Schwartz MM, Korbet SM, and the Lupus Nephritis Collaborative Study Group. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996; 7: 299-305.
7. Pasquali S, Banfi G, Zucchelli A Moroni G, Panticelli C, Zucchelli, P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-82.
8. Roman MJ, Shanker B, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349: 2399-2406.
9. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-115.
10. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort. Arthritis Rheum 1995; 38: 1492-99.
11. Tang S, Leung JCK, Abe K et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells: an in vitro and in vivo study. J Clin Invest 2003; 111: 515-27.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde, RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New Engl J Med 1993; 329: 1456-62.
13. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
14. Maschio G, Alberti D, Janin G, and The Angiotensin-Converting-Enzyme Inhibition In Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New Engl J Med 1996; 334: 939-45.
15. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345: 851-60.
16. Brenner BM, Cooper ME, de Zeeuw D and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345: 861-69.
17. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-87.
18. Kanda H, Kubo K, Tateishi S et al. Antiprotienuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 143: 288-99.
19. Chan TM, Li FK, Wong RWS, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-27.
20. Chan TM, Tse KC, Tang CSO, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-72.
21. Zar JH. Comparing simple linear regression equations. In Biostatistical analysis. Prentice-Hall, 1999; 360-76.
22. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. Analysis of repeated measures data. In SAS svstem for mixed models. Cary NC: SAS Institute Inc. 1996; 87-134.
23. SAS. The MIXED procedure. In SAS/STAT user's guide. Version 8. Cary NC: SAS Institute Inc., 1999, Chapter 41.
24. Austin HA III, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Am J Med 1983; 75: 382-91.
25. Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002; 13: S190-95.
26. Wolf G, Butzmann U, Wenzel UO. The rennin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93: P3-13.
27. Remuzzi A, Perico N, Sangalli F et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999; 276: F457-66.
28. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001; 59: 2282-89.
29. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-24.
30. Gossmann J, Thurmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme-related anaemia in renal transplant recipients. Kidney Int 1996; 50: 973-78.
31. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352: 286.